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Figure 1. Palmar aspect of necrotiz-
ing lesion.
Figure 2. Lateral aspect of necrotiz-
ing lesion.
Figure 3. Dorsal aspect of necrotiz-
ing lesion.
DESCRIPTION
A 65-year-old man presented with a left nontraumatic thumb lesion. Inflammatory markers
were raised and infection was initially diagnosed. Despite surgical debridements and intra-
venous antibiotics, wounds deteriorated, extending to his index finger. Microbiology and
histology were nonspecific. A diagnosis of pyoderma gangrenosum (PG) was made and
successful treatment with steroids was initiated.
QUESTIONS
1. What is PG?
2. How is PG diagnosed?
3. What are the clinical and histological features of PG?
4. How is PG managed?
DISCUSSION
Pyoderma gangrenosum is a rare, autoimmune, ulcerative, neutrophilic dermatosis of un-
known aetiology. Initial presentation of PG is as small papules, which subsequently coa-
lesce, break down, and undergo liquefactive necrosis to form ulcers.1 It has an estimated
incidence of 3 to 10 cases per million worldwide and mainly affects adults, affecting men
and women equally. Its peak onset is at 50 years of age.2 There are 5 clinical subtypes:
ulcerative, peristomal, pustular, bullous, and vegetative. It is a rapidly progressive disease
with irregular, erythematous undermined borders that can occur on any skin surface.1
Pyoderma gangrenosum is a diagnosis of exclusion and no laboratory test has been
developed for its diagnosis.3 As illustrated by this case, PG is often not recognized immedi-
ately. This delay in diagnosis can have significant consequences.1 Although PG has a typical
clinical appearance (discussed below), there are other conditions that present with similar
features. Differential diagnoses include Behcet’s, vasculitis, mixed cryoglobulinaemia, lu-
pus, cutaneous infection such as ecthyma, blastomycosis, or herpes simplex, vascular or
arterial ulceration, or cutaneous malignancy.3 An essential differential diagnosis of PG and
possibility in our patient is Sweet syndrome: another neutrophilic dermatosis presenting
with red papules and plaques, more commonly on the dorsum of the hand.2 Presently, PG
lacks international diagnostic criteria, but some have been proposed, split into major and
minor criteria. Major criteria include rapidly developing ulcers and the ruling-out of other
ulcerative skin conditions. Minor criteria include pathergy (a nonspecific hypersensitivity
reaction of skin to minimal trauma, leading to persistent ulceration at the site of surgical
incision), systemic disease associated with PG, and more.3
Patients often present systemically unwell, with a fever.1 Lesions are painful, often
severely so, and are disproportionate to the size of the lesion. Ulcers subsequently heal with
cribriform scarring.3 In 50% to 70% of cases, PG presents with underlying inflammatory
bowel disease, haematological malignancies, or rheumatologic disease.2 Extracutaneous
manifestations may occur, including in the spleen, in the lungs as pulmonary nodules, or
in the eyes as scleritis.4 Inflammatory markers, including C-reactive protein, erythrocyte
sedimentation rate, and white blood cell count are raised. Furthermore, patients with PG
may have raised autoantibodies (particularly p-ANCA) if inflammatory bowel disease is
present. Histological appearance is contingent upon the subtype of PG aswell as the time the
skin biopsy is taken: early lesions show moderate lymphocytic infiltration with oedema and
thrombosis. Infarction and abscesses occur in later ulceration, with antibodies such as IgM
found in dermal blood vessels, suggesting an immunological pathogenesis.5 Clonal T-cell
expansions have also been described in some PG lesions.2 However, these findings are not
specific to PG. It is important to note that review by a dermopathologist is recommended
over standard pathologic interpretation.
Surgery is contraindicated in PG: as in our patient, PG can persist and enlarge with
debridement.6 Treatment is largely empirical in nature.1 PG should be treated according
to local guidelines as there is currently no gold standard of treatment.4 Smaller lesions
may be managed with topical steroid preparations or intra-lesional steroid injections (hence
why when taking a biopsy from a suspected PG lesion, using an injectable corticosteroid
is recommended to contain a possible pathergy reaction). Larger and multiple lesions may
require long-term systemic immunosuppressive drugs: for example, either oral prednisolone
0.75mg/kg/day in a single dose or ciclosporin 4mg/kg/day in two divided doses. This can be
adjusted to a maximum of 1 mg/kg/day for prednisolone and 5 mg/kg/day for cyclosporin.7
More recently, monoclonal antibodies targeting tumor necrosis factor α, such as infliximab,
have been shown to be safe and effective treatments for PG.8 Management of underlying
disease and pain management of lesions are also essential.4
SUMMARY
As illustrated by this case, cutaneous PGof the hand is a diagnosis of exclusion. Though rare,
an index of suspicion should be maintained as PG can present similarly to other conditions
in the hand such as fulminating infection and malignancy, that would traditionally be
managed surgically. Inappropriate surgical debridement of PG in the hand can, however,
lead to persistent and worsening ulceration and poor outcomes, such as digital amputation,
so should be avoided. Although international diagnostic criteria are yet to be established,
prompt diagnosis is essential in avoiding significant clinical consequences.
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